Literature DB >> 28694273

Barriers Rural Physicians Face Prescribing Buprenorphine for Opioid Use Disorder.

C Holly A Andrilla1, Cynthia Coulthard2, Eric H Larson2.   

Abstract

Opioid use disorder is a serious public health problem. Management with buprenorphine is an effective, office-based, medication-assisted treatment, but 60.1% of rural counties in the United States lack a physician with a Drug Enforcement Agency waiver to prescribe buprenorphine. This national study surveyed all rural physicians who have received a waiver in the United States and found that those who were not actively prescribing buprenorphine reported significantly more barriers than those who were, regardless of whether they were treating the maximum number of patients their waiver allowed. These findings suggest the need for tailored strategies to address barriers to providing buprenorphine for opioid use disorder and to support physicians who are adding or maintaining this service.
© 2017 Annals of Family Medicine, Inc.

Entities:  

Keywords:  buprenorphine; medication-assisted treatment; mental health care; opiate addiction; opiate substitution treatment; opioid treatment programs; rural health

Mesh:

Substances:

Year:  2017        PMID: 28694273      PMCID: PMC5505456          DOI: 10.1370/afm.2099

Source DB:  PubMed          Journal:  Ann Fam Med        ISSN: 1544-1709            Impact factor:   5.166


  9 in total

1.  Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians.

Authors:  Cynthia L Arfken; Chris-Ellyn Johanson; Salvatore di Menza; Charles Roberts Schuster
Journal:  J Subst Abuse Treat       Date:  2010-07-03

2.  Buprenorphine therapy for opioid addiction in rural Washington: the experience of the early adopters.

Authors:  Tyler L Quest; Joseph O Merrill; John Roll; Andrew J Saxon; Roger A Rosenblatt
Journal:  J Opioid Manag       Date:  2012 Jan-Feb

3.  Barriers to primary care physicians prescribing buprenorphine.

Authors:  Eliza Hutchinson; Mary Catlin; C Holly A Andrilla; Laura-Mae Baldwin; Roger A Rosenblatt
Journal:  Ann Fam Med       Date:  2014 Mar-Apr       Impact factor: 5.166

4.  Geographic and specialty distribution of US physicians trained to treat opioid use disorder.

Authors:  Roger A Rosenblatt; C Holly A Andrilla; Mary Catlin; Eric H Larson
Journal:  Ann Fam Med       Date:  2015 Jan-Feb       Impact factor: 5.166

5.  Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.

Authors:  Bradley D Stein; Rosalie Liccardo Pacula; Adam J Gordon; Rachel M Burns; Douglas L Leslie; Mark J Sorbero; Sebastian Bauhoff; Todd W Mandell; Andrew W Dick
Journal:  Milbank Q       Date:  2015-09       Impact factor: 4.911

Review 6.  Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.

Authors:  Jeffrey R DeFlavio; Stephanie A Rolin; Benjamin R Nordstrom; Louis A Kazal
Journal:  Rural Remote Health       Date:  2015-02-04       Impact factor: 1.759

Review 7.  Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies.

Authors:  Xiaofan Li; Daryl Shorter; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2014-08-29       Impact factor: 3.889

8.  Office-based management of opioid dependence with buprenorphine: clinical practices and barriers.

Authors:  Alexander Y Walley; Julie K Alperen; Debbie M Cheng; Michael Botticelli; Carolyn Castro-Donlan; Jeffrey H Samet; Daniel P Alford
Journal:  J Gen Intern Med       Date:  2008-09       Impact factor: 5.128

Review 9.  Medication-assisted treatment with buprenorphine: assessing the evidence.

Authors:  Cindy Parks Thomas; Catherine Anne Fullerton; Meelee Kim; Leslie Montejano; D Russell Lyman; Richard H Dougherty; Allen S Daniels; Sushmita Shoma Ghose; Miriam E Delphin-Rittmon
Journal:  Psychiatr Serv       Date:  2014-02-01       Impact factor: 3.084

  9 in total
  52 in total

1.  West Virginia's model of buprenorphine expansion: Preliminary results.

Authors:  Erin L Winstanley; Laura R Lander; James H Berry; James J Mahoney; Wanhong Zheng; Jeremy Herschler; Patrick Marshalek; Sheena Sayres; Jay Mason; Marc W Haut
Journal:  J Subst Abuse Treat       Date:  2019-05-08

Review 2.  Challenges Facing a Rural Opioid Epidemic: Treatment and Prevention of HIV and Hepatitis C.

Authors:  Asher J Schranz; Jessica Barrett; Christopher B Hurt; Carlos Malvestutto; William C Miller
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

3.  Now is the Time to Address Substance Use Disorders in Primary Care.

Authors:  Richard Saitz; Timothy P Daaleman
Journal:  Ann Fam Med       Date:  2017-07       Impact factor: 5.166

4.  The Promise of Technology-Based Services for Addiction Treatment Clients Residing in Nonurban Areas.

Authors:  Erin L Winstanley; Beth Stroup-Menge; Kurt Snyder
Journal:  J Stud Alcohol Drugs       Date:  2018-05       Impact factor: 2.582

5.  Financing Buprenorphine Treatment in Primary Care: A Microsimulation Model.

Authors:  Jonathan E Fried; Sanjay Basu; Russell S Phillips; Bruce E Landon
Journal:  Ann Fam Med       Date:  2020-11       Impact factor: 5.166

6.  Barriers to Buprenorphine Expansion in Ohio: A Time-Elapsed Qualitative Study.

Authors:  Todd Molfenter; Maureen Fitzgerald; Nora Jacobson; Dennis McCarty; Andrew Quanbeck; Mark Zehner
Journal:  J Psychoactive Drugs       Date:  2019-02-07

7.  The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.

Authors:  Alex K Gertner; Allison G Robertson; Hendree Jones; Byron J Powell; Pam Silberman; Marisa E Domino
Journal:  Health Serv Res       Date:  2020-03-12       Impact factor: 3.402

8.  Perceptions and practices addressing diversion among US buprenorphine prescribers.

Authors:  Lewei Allison Lin; Michelle R Lofwall; Sharon L Walsh; Adam J Gordon; Hannah K Knudsen
Journal:  Drug Alcohol Depend       Date:  2018-03-10       Impact factor: 4.492

9.  Trends in Abstinence and Retention Associated with a Medication-Assisted Treatment Program for People with Opioid Use Disorders.

Authors:  Kimberly D Brunisholz; Andrew J Knighton; Amulya Sharma; Lisa Nichols; Kristen Reisig; Jed Burton; Debbie Scovill; Carolyn Tometich; Mark Foote; Shelly Read; Scott Whittle
Journal:  Prog Community Health Partnersh       Date:  2020

10.  Multi-model implementation of evidence-based care in the treatment of opioid use disorder in Pennsylvania.

Authors:  Sarah Kawasaki; Erica Francis; Sara Mills; Glenn Buchberger; Ruth Hogentogler; Jennifer Kraschnewski
Journal:  J Subst Abuse Treat       Date:  2019-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.